Prevention of Dopamine Dysregulation Syndrome in Parkinson's Disease: A Case Report

Because this piece does not have an abstract, we have provided for your benefit the first 3 sentences of the full text.

To the Editor: Parkinson’s disease (PD) is a common neurodegenerative disease that affects 1 million people in the United States. The current recommended treatments for PD are carbidopa/levodopa and dopamine agonists. While carbidopa/levodopa is relatively safe for PD patients, dopamine agonists have been associated with many adverse effects such as hallucinations, compulsive behaviors, orthostatic hypotension, somnolence, peripheral edema, and nausea.